Arbutus Biopharma Corp (ABUS) Expected to Post Q1 2017 Earnings of ($0.38) Per Share

Arbutus Biopharma Corp (NASDAQ:ABUS) – Equities researchers at Leerink Swann issued their Q1 2017 EPS estimates for shares of Arbutus Biopharma Corp in a report issued on Wednesday, according to Zacks Investment Research. Leerink Swann analyst M. Schmidt expects that the biopharmaceutical company will earn ($0.38) per share for the quarter. Leerink Swann also issued estimates for Arbutus Biopharma Corp’s Q2 2017 earnings at ($0.40) EPS.

Several other research firms also recently commented on ABUS. Zacks Investment Research raised shares of Arbutus Biopharma Corp from a “sell” rating to a “hold” rating in a report on Friday, February 17th. Wedbush reissued an “outperform” rating and set a $10.00 price objective (up previously from $9.00) on shares of Arbutus Biopharma Corp in a report on Wednesday, March 22nd. Bloom Burton raised shares of Arbutus Biopharma Corp from an “accumulate” rating to a “buy” rating in a report on Monday, January 9th. Finally, Chardan Capital raised shares of Arbutus Biopharma Corp from a “neutral” rating to a “buy” rating and increased their price objective for the company from $3.00 to $6.00 in a report on Tuesday, April 4th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $6.25.

Earnings History and Estimates for Arbutus Biopharma Corp (NASDAQ:ABUS)

COPYRIGHT VIOLATION WARNING: “Arbutus Biopharma Corp (ABUS) Expected to Post Q1 2017 Earnings of ($0.38) Per Share” was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.com-unik.info/2017/04/21/analysts-offer-predictions-for-arbutus-biopharma-corps-q1-2017-earnings-abus-updated-updated.html.

Arbutus Biopharma Corp (NASDAQ:ABUS) traded down 1.49% during trading on Thursday, hitting $3.30. The stock had a trading volume of 179,664 shares. Arbutus Biopharma Corp has a 52-week low of $2.35 and a 52-week high of $5.48. The company has a 50-day moving average price of $3.10 and a 200-day moving average price of $2.88. The company’s market cap is $181.58 million.

Several hedge funds have recently made changes to their positions in ABUS. Bank of Montreal Can boosted its stake in shares of Arbutus Biopharma Corp by 6.3% in the third quarter. Bank of Montreal Can now owns 861,553 shares of the biopharmaceutical company’s stock valued at $2,964,000 after buying an additional 50,768 shares in the last quarter. Baker BROS. Advisors LP acquired a new stake in shares of Arbutus Biopharma Corp during the third quarter valued at about $621,000. K2 Principal Fund L.P. boosted its stake in shares of Arbutus Biopharma Corp by 69.3% in the third quarter. K2 Principal Fund L.P. now owns 107,620 shares of the biopharmaceutical company’s stock valued at $370,000 after buying an additional 44,070 shares in the last quarter. Oxford Asset Management acquired a new stake in shares of Arbutus Biopharma Corp during the fourth quarter valued at about $392,000. Finally, Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of Arbutus Biopharma Corp by 1,058,889.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 5,294,945 shares of the biopharmaceutical company’s stock valued at $12,972,000 after buying an additional 5,294,445 shares in the last quarter. Hedge funds and other institutional investors own 61.24% of the company’s stock.

About Arbutus Biopharma Corp

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

5 Day Chart for NASDAQ:ABUS

Get a free copy of the Zacks research report on Arbutus Biopharma Corp (ABUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Arbutus Biopharma Corp? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Arbutus Biopharma Corp and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit